-

Lumenis Launches MOSES™ HoLEP University to Help Urologists Master the Gold-Standard Laser Treatment for Enlarged Prostate

Peer-led global educational platform focuses on the use of award-winning MOSES laser technology

YOKNE'AM ILLIT, Israel--(BUSINESS WIRE)--Lumenis, the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, today announced the launch of a comprehensive global educational platform called MOSES HoLEP University that will enable urologists to offer their patients holmium laser enucleation of the prostate (HoLEP) with MOSES, the gold-standard treatment for enlarged prostate (benign prostatic hyperplasia, or BPH). By making HoLEP training available to any urologist at any time, the program will fill an educational gap. While interest in the procedure is expanding by 8% to 12% per year,1 opportunities for training remain limited due to restricted hospital foot traffic and travel during the COVID-19 pandemic.2

Lumenis responded to this demand for HoLEP education by joining forces with world-renowned physicians and BPH specialists Dr. Amy Krambeck of Northwestern Medicine and Dr. Tim Large of Indiana University Health. With help from Dr. Large, Dr. Krambeck will lead a one-of-a-kind opportunity for surgeons to master HoLEP through MOSES HoLEP University, an online, on-demand, module-based educational platform. Surgeons will observe a HoLEP procedure step by step, allowing them to achieve a full understanding of the technique. Training will be free to Lumenis customers using MOSES laser technology, winner of the prestigious Silver 2021 Medical Design Excellence Award in Gastrointestinal and Genitourinary Devices.

“MOSES HoLEP University was designed to facilitate more comprehensive learning with a faster learning curve,”3 said Dr. Krambeck. “Training will support urologists’ ability to effectively and efficiently perform HoLEP in men with BPH, regardless of their prostate size4 or history of taking blood thinners.”5

Accessed on demand, MOSES HoLEP University’s 14 modules explain how to perform different HoLEP techniques, including morcellation strategies, as well as how to set up a HoLEP practice, troubleshoot, and manage patient follow-up and concerns. In addition, trainees are invited to attend a MOSES Mastery course for hands-on lab and simulation experience. Following completion of MOSES HoLEP University, physicians can become adept at the HoLEP technique after 20 to 30 supervised procedures.6 In the future, each participant will be assigned a HoLEP mentor who can assist remotely with challenges.

HoLEP is a trusted procedure that has been improved by Lumenis MOSES technology. The Lumenis Pulse 120H laser with MOSES 2.0 technology shortens HoLEP procedure time by 20%, increases the rate of enucleation efficiency by 67%, and minimizes bleeding by 30%.7 As a result, more than 90% of patients can go home the same day, catheter-free,8 and only 0.7% of patients need retreatment in the next 10 years.9 MOSES has won multiple awards as a groundbreaking medical technology that is changing patient care.

“We are extremely proud to introduce this first-of-its-kind educational opportunity for surgeons who want to learn HoLEP with our breakthrough MOSES laser technology,” said Lumenis CEO Tzipi Ozer-Armon. “With unparalleled mentorship from recognized experts, MOSES HoLEP University will help surgeons satisfy patient demand for this important treatment, provide superior clinical outcomes, and elevate their practices.”

About Lumenis

Lumenis is a global leader in the field of minimally invasive clinical solutions for the surgical, ophthalmology, and aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including laser, intense pulsed light (IPL), and radio frequency (RF). For 50+ years, Lumenis' groundbreaking products have redefined medical treatments and set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information, visit www.lumenis.com.

References:

1. IQVIA™ Hospital Procedures & Diagnosis US claims data coverage 2017-2019 (inpatient & outpatient).

2. Adopting Gold-Standard Procedures During COVID-19 - Patient Safety & Quality Healthcare (psqh.com).

3. Krambeck AE, Large T. Urology. 2020;136:196-201.

4. Elzayat EA, et al. Urology. 2005;66(5):108-113.

5. The HoLEP Procedure - Advanced Urology Institute - (auinstitute.com).

6. El-Hakim A., et al. BJU Int. 2002;90(9):863-9.

7. Kavoussi NL, et al. J Urol. 2021;206(1):104-108.8. Agarwal DK, et al. Eur Urol Focus. 2021 Jan 4.

8. Agarwal DK, et al. Eur Urol Focus. 2021 Jan 4.

9. Elmansy HM, et al. J Urol. 2011;186(5):1972-1976.

Contacts

Genevieve Britton
+1.512.774.0735 (c)
genevieve@pascalecommunications.com

Lumenis


Release Versions

Contacts

Genevieve Britton
+1.512.774.0735 (c)
genevieve@pascalecommunications.com

More News From Lumenis

Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology

YOKNE’AM ILLIT, Israel--(BUSINESS WIRE)--Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The w...

Mandy Moore Partners With Lumenis to Raise Awareness of Dry Eye Disease and OptiLight Treatment

YOKNE’AM ILLIT, Israel--(BUSINESS WIRE)--Lumenis today announced that it has partnered with singer-songwriter and actress Mandy Moore as a brand ambassador for OptiLight, a bright solution for dry eyes. Ms. Moore suffered from dry eye disease and treatment with OptiLight significantly improved her condition. Now she’s partnering with Lumenis to share her story and empower others. She will star in OptiLight’s new campaign, showing millions of dry eye sufferers that they don’t have to “just live...

Urology of St. Louis is First Facility in Region to Adopt Innovative New Laser Treatment for Enlarged Prostate

ST. LOUIS--(BUSINESS WIRE)--Urology of St. Louis (USL), the largest private urologic practice in St. Louis and the Metro East, has become the only facility in the region to conduct surgery for benign enlarged prostate using the MOSES™ 2.0 Pulse 120H by Lumenis, an advancement in minimally invasive laser technology. In 2019, William Critchlow, M.D., of USL, became one of the first physicians in St. Louis and the surrounding region to offer holmium laser enucleation of the prostate (HoLEP), a spe...
Back to Newsroom